Pomanda estimates the enterprise value of NEWCELLS BIOTECH LIMITED at £6m based on a Turnover of £4.2m and 1.44x industry multiple (adjusted for size and gross margin).
newcells biotech limitedEstimated Valuation
£0
Pomanda estimates the enterprise value of NEWCELLS BIOTECH LIMITED at £0 based on an EBITDA of £-2.3m and a 5.68x industry multiple (adjusted for size and gross margin).
newcells biotech limitedEstimated Valuation
£6.5m
Pomanda estimates the enterprise value of NEWCELLS BIOTECH LIMITED at £6.5m based on Net Assets of £3.6m and 1.79x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Newcells Biotech LimitedOverview
Newcells Biotech Limited is a live company located in tyne and wear, NE1 4BF with a Companies House number of 09389592. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in January 2015, it's largest shareholder is
northern venture trust plc
with a 18.5% stake. Newcells Biotech Limited is a established,
small sized company, Pomanda has estimated its turnover at
£4.2m with
rapid
growth in recent years.
Pomanda's financial health check has awarded Newcells Biotech Limited a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 3 areas for improvement. Company Health Check FAQs
Health Rating4.5out of 5
4 Strong
5 Regular
3 Weak
Size
annual sales of £4.2m, make it in line with the average company (£4.1m)
£4.2m - Newcells Biotech Limited
£4.1m - Industry AVG
Growth
3 year (CAGR) sales growth of 32%, show it is growing at a faster rate (12.3%)
32% - Newcells Biotech Limited
12.3% - Industry AVG
Production
with a gross margin of 54.2%, this company has a comparable cost of product (54.2%)
54.2% - Newcells Biotech Limited
54.2% - Industry AVG
Profitability
an operating margin of -58.4% make it less profitable than the average company (-7%)
-58.4% - Newcells Biotech Limited
-7% - Industry AVG
Employees
with 44 employees, this is similar to the industry average (49)
44 - Newcells Biotech Limited
49 - Industry AVG
Pay Structure
on an average salary of £82.4k, the company has an equivalent pay structure (£82.4k)
£82.4k - Newcells Biotech Limited
£82.4k - Industry AVG
Efficiency
resulting in sales per employee of £95.3k, this is less efficient (£127.9k)
£95.3k - Newcells Biotech Limited
£127.9k - Industry AVG
Debtor Days
it gets paid by customers after 60 days, this is near the average (53 days)
60 days - Newcells Biotech Limited
53 days - Industry AVG
Creditor Days
its suppliers are paid after 69 days, this is slower than average (52 days)
69 days - Newcells Biotech Limited
52 days - Industry AVG
Stock Days
it holds stock equivalent to 68 days, this is more than average (53 days)
68 days - Newcells Biotech Limited
53 days - Industry AVG
Cash Balance
has cash to cover current liabilities
for 112 weeks, this is more cash available to meet short term requirements (30 weeks)
112 weeks - Newcells Biotech Limited
30 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 21.6%, this is a lower level of debt than the average (52.2%)
21.6% - Newcells Biotech Limited
52.2% - Industry AVG
NEWCELLS BIOTECH LIMITED financials
EXPORT
Newcells Biotech Limited's latest turnover from January 2024 is estimated at £4.2 million and the company has net assets of £3.6 million. According to their latest financial statements, Newcells Biotech Limited has 44 employees and maintains cash reserves of £2.1 million as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Jan 2024
Jan 2023
Jan 2022
Jan 2021
Jan 2020
Jan 2019
Jan 2018
Jan 2017
Jan 2016
Turnover
4,194,027
3,853,697
2,695,441
1,826,408
1,311,040
833,520
232,448
435,668
213,701
Other Income Or Grants
Cost Of Sales
1,922,825
1,834,032
1,383,464
850,187
643,535
384,107
109,662
226,181
119,151
Gross Profit
2,271,202
2,019,665
1,311,977
976,221
667,504
449,413
122,786
209,487
94,550
Admin Expenses
4,722,344
4,482,365
3,409,785
2,109,854
1,284,270
707,293
87,298
237,468
135,786
Operating Profit
-2,451,142
-2,462,700
-2,097,808
-1,133,633
-616,766
-257,880
35,488
-27,981
-41,236
Interest Payable
154,815
131,682
2,917
1,525
94
94
Interest Receivable
114,304
71,872
8,622
3,110
10,918
8,794
1,962
332
302
Pre-Tax Profit
-2,491,653
-2,522,510
-2,092,103
-1,132,048
-605,942
-249,180
37,449
-27,649
-40,934
Tax
-7,115
Profit After Tax
-2,491,653
-2,522,510
-2,092,103
-1,132,048
-605,942
-249,180
30,334
-27,649
-40,934
Dividends Paid
Retained Profit
-2,491,653
-2,522,510
-2,092,103
-1,132,048
-605,942
-249,180
30,334
-27,649
-40,934
Employee Costs
3,626,658
3,160,920
2,756,499
1,532,637
1,015,691
543,314
249,060
174,797
161,802
Number Of Employees
44
42
35
22
15
8
4
3
3
EBITDA*
-2,288,847
-2,281,719
-1,818,698
-952,387
-573,441
-236,736
38,605
-27,541
-41,236
* Earnings Before Interest, Tax, Depreciation and Amortisation
Jan 2024
Jan 2023
Jan 2022
Jan 2021
Jan 2020
Jan 2019
Jan 2018
Jan 2017
Jan 2016
Tangible Assets
425,237
441,313
605,044
432,561
258,935
38,375
33,470
1,025
1,291
Intangible Assets
5,325
23,986
50,649
77,312
103,976
72,003
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets
430,562
465,299
655,693
509,873
362,911
110,378
33,470
1,025
1,291
Stock & work in progress
362,885
426,807
254,598
71,768
79,234
49,212
22,522
Trade Debtors
691,569
604,325
305,445
271,573
192,330
192,136
7,650
118,411
Group Debtors
Misc Debtors
1,022,111
618,080
563,993
287,583
122,933
103,200
35,503
13
13
Cash
2,131,997
2,222,434
1,884,565
5,012,703
1,206,326
1,705,161
640,002
144,646
120,628
misc current assets
412
total current assets
4,208,562
3,871,646
3,008,601
5,643,627
1,600,823
2,049,709
705,677
263,070
121,053
total assets
4,639,124
4,336,945
3,664,294
6,153,500
1,963,734
2,160,087
739,147
264,095
122,344
Bank overdraft
2,798
Bank loan
10,000
10,000
10,000
6,667
Trade Creditors
366,730
308,487
170,037
505,399
129,740
30,761
32,178
8,340
8,453
Group/Directors Accounts
other short term finances
hp & lease commitments
83,229
119,996
168,910
92,452
other current liabilities
521,217
371,651
357,857
459,557
639,382
449,745
591,725
170,845
1,332
total current liabilities
981,176
810,134
706,804
1,064,075
769,122
483,304
623,903
179,185
9,785
loans
13,334
2,718,928
33,333
43,333
hp & lease commitments
6,966
90,194
89,833
72,312
Accruals and Deferred Income
1,213
51,566
85,771
other liabilities
18,000
provisions
total long term liabilities
20,300
2,809,122
124,379
167,211
103,771
total liabilities
1,001,476
3,619,256
831,183
1,231,286
872,893
483,304
623,903
179,185
9,785
net assets
3,637,648
717,689
2,833,111
4,922,214
1,090,841
1,676,783
115,244
84,910
112,559
total shareholders funds
3,637,648
717,689
2,833,111
4,922,214
1,090,841
1,676,783
115,244
84,910
112,559
Jan 2024
Jan 2023
Jan 2022
Jan 2021
Jan 2020
Jan 2019
Jan 2018
Jan 2017
Jan 2016
Operating Activities
Operating Profit
-2,451,142
-2,462,700
-2,097,808
-1,133,633
-616,766
-257,880
35,488
-27,981
-41,236
Depreciation
143,634
154,318
252,447
154,582
22,025
13,146
3,117
440
Amortisation
18,661
26,663
26,663
26,664
21,300
7,998
Tax
-7,115
Stock
-63,922
172,209
182,830
-7,466
30,022
26,690
22,522
Debtors
491,275
352,967
310,282
243,893
19,927
252,183
-75,271
118,411
13
Creditors
58,243
138,450
-335,362
375,659
98,979
-1,417
23,838
-113
8,453
Accruals and Deferred Income
149,566
12,581
-152,053
-214,030
275,408
-141,980
420,880
169,513
1,332
Deferred Taxes & Provisions
Cash flow from operations
-2,508,391
-2,655,864
-2,799,225
-1,027,185
-249,003
-659,006
528,957
23,448
-31,464
Investing Activities
capital expenditure
-127,558
9,413
-424,930
-328,208
-295,858
-98,052
-35,562
-174
-1,291
Change in Investments
cash flow from investments
-127,558
9,413
-424,930
-328,208
-295,858
-98,052
-35,562
-174
-1,291
Financing Activities
Bank loans
3,333
6,667
Group/Directors Accounts
Other Short Term Loans
Long term loans
-2,705,594
2,685,595
-10,000
43,333
Hire Purchase and Lease Commitments
-119,995
-48,553
93,979
164,764
other long term liabilities
-18,000
18,000
share issue
5,411,612
407,088
3,000
4,963,421
20,000
1,810,719
153,493
interest
-40,511
-59,810
5,705
1,585
10,824
8,700
1,962
332
302
cash flow from financing
2,545,512
2,984,320
96,017
5,161,770
48,824
1,819,419
1,962
332
153,795
cash and cash equivalents
cash
-90,437
337,869
-3,128,138
3,806,377
-498,835
1,065,159
495,356
24,018
120,628
overdraft
-2,798
2,798
change in cash
-90,437
337,869
-3,128,138
3,806,377
-496,037
1,062,361
495,356
24,018
120,628
newcells biotech limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for newcells biotech limited. Get real-time insights into newcells biotech limited's credit score, group structure and payment trends.
Perform a competitor analysis for newcells biotech limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in NE1 area or any other competitors across 12 key performance metrics.
newcells biotech limited Ownership
NEWCELLS BIOTECH LIMITED group structure
Newcells Biotech Limited has no subsidiary companies.
Ultimate parent company
NEWCELLS BIOTECH LIMITED
09389592
NEWCELLS BIOTECH LIMITED Shareholders
The largest shareholders in Newcells Biotech Limited include Northern Venture Trust Plc and Northern 2 Vct Plc.
northern venture trust plc
18.54%
northern 2 vct plc
16.87%
northern 3 vct plc
16.66%
the north east (erdf) innovation fund limited partnership acting through innovation gp limited
13.42%
the north east (erdf) venture capital limited partnership limited
10.56%
lyle armstrong
9.52%
the north east accelerator limited partnership
3.68%
michael john nicholds
3.64%
newcastle university holdings limited
3.38%
mnl (mercia) nominees limited
2.79%
newcells biotech limited directors
Newcells Biotech Limited currently has 6 directors.
The longest serving directors include
Professor Lyle Armstrong (Jan 2015) and
Dr Michael Nicholds (Jan 2015).
72110 - Research and experimental development on biotechnology
incorporation date
January 2015
age
10
incorporated
UK
ultimate parent company
None
accounts
Small Company
last accounts submitted
January 2024
previous names
N/A
accountant
-
auditor
RYECROFT GLENTON
address
time central 32 gallowgate, newcastle upon tyne, tyne and wear, NE1 4BF
Bank
-
Legal Advisor
-
newcells biotech limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to newcells biotech limited. Currently there are 1 open charges and 1 have been satisfied in the past.
newcells biotech limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for NEWCELLS BIOTECH LIMITED. This can take several minutes, an email will notify you when this has completed.
newcells biotech limitedCompanies House Filings - See Documents
